|
Facilitative Transporters: Class 1 GLUTs |
|
| Major site of expression | Expression in EOC [77ā80] | Localization in EOC [77ā80] | Expression in other cancers |
GLUT-1 | Fetal tissue, erythrocytes; widely distributed | Overexpressed in almost all invasive carcinomas; expression increases from benign to invasive tumours | Cell membrane, cytoplasm; more in membrane in more invasive; some studies say stronger closer to periphery; some say farther from tumour-stromal interface | Breast [82, 83], head, and neck [84], colorectal [85], prostate [86], pancreatic [87], cervical [88] |
GLUT-2 | Liver, pancreas | Negative | Unknown | Islet cell tumours [89], sarcoma [90] |
GLUT-3 | Brain | Conflicting: reported to be high in >90% of EOC tumours; also weak, homogenous expression in all ovarian tissue; also in ovarian tumours but not normal tissue | Cytoplasm and cell membrane | Lymphoma [91], head and neck [92], lung [93] |
GLUT-4 | Insulin-responsive tissues (skeletal muscle, heart, adipose tissue) | Conflicting: no expression in normal or malignant; also present in up to 84% in ovarian tumour cells | Unknown | Lung [94], breast [95] |
|
Active Transporters: SGLTs. |
|
| Major site of expression | Expression in EOC | Localization in EOC | Expression in other cancers |
SGLT1 | Kidney and small intestine | Not investigated | Unknown | Breast [96], prostate [96], head and neck [97], pancreatic [98] |
SGLT2 | Kidney and small intestine | Not investigated | Unknown | No reports |
SGLT3 | Skeletal muscle and small intestine | Not investigated | Unknown | No reports |
|